MT-026

N/A

Report date: 2023/02/22 10:38:27

Base Information

Drug NameMT-026
Drug Alias NameMT-026
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-IL13RA2
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A